Detalhe da pesquisa
1.
Immune Response Evaluation and Treatment with Immune Checkpoint Inhibitors Beyond Clinical Progression: Response Assessments for Cancer Immunotherapy.
Curr Oncol Rep
; 22(11): 116, 2020 08 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-32851542
2.
FDA Approval Summary: Tremelimumab in Combination with Durvalumab for the Treatment of Patients with Unresectable Hepatocellular Carcinoma.
Clin Cancer Res
; 30(2): 269-273, 2024 01 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-37676259
3.
FDA Approval Summary: Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer.
Clin Cancer Res
; 2024 May 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38809262
4.
FDA Approval Summary: Ripretinib for Advanced Gastrointestinal Stromal Tumor.
Clin Cancer Res
; 29(11): 2020-2024, 2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36485007
5.
FDA Approval Summary: Futibatinib for Unresectable Advanced or Metastatic, Chemotherapy Refractory Intrahepatic Cholangiocarcinoma with FGFR2 Fusions or Other Rearrangements.
Clin Cancer Res
; 29(20): 4027-4031, 2023 Oct 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37289037
6.
FDA Approval Summary: Tucatinib with Trastuzumab for Advanced Unresectable or Metastatic, Chemotherapy Refractory, HER2-Positive RAS Wild-Type Colorectal Cancer.
Clin Cancer Res
; 29(21): 4326-4330, 2023 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37318379
7.
FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement.
Clin Cancer Res
; 29(5): 838-842, 2023 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36206041
8.
Highlights of FDA Oncology Approvals in 2023: Bispecific T-cell Engagers, Pediatric Indications, and Inclusive Drug Development.
Cancer Discov
; 13(12): 2515-2524, 2023 12 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38084090
9.
FDA Approval Summary: Selpercatinib for the Treatment of Advanced RET Fusion-Positive Solid Tumors.
Clin Cancer Res
; 29(18): 3573-3578, 2023 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37265412
10.
FDA Approval Summary: Nivolumab for the Adjuvant Treatment of Adults with Completely Resected Esophageal/Gastroesophageal Junction Cancer and Residual Pathologic Disease.
Clin Cancer Res
; 28(24): 5244-5248, 2022 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35960160
11.
FDA Approval Summary: Ivosidenib for the Treatment of Patients with Advanced Unresectable or Metastatic, Chemotherapy Refractory Cholangiocarcinoma with an IDH1 Mutation.
Clin Cancer Res
; 28(13): 2733-2737, 2022 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35259259
12.
A pilot study evaluating the safety and CD34+ cell mobilizing activity of escalating doses of plerixafor in healthy volunteers.
Br J Haematol
; 153(1): 66-75, 2011 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-21352197
13.
U.S. Food and drug administration approval: rituximab in combination with fludarabine and cyclophosphamide for the treatment of patients with chronic lymphocytic leukemia.
Oncologist
; 16(1): 97-104, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-21212432
14.
Tissue-Agnostic Drug Development: A New Path to Drug Approval.
Cancer Discov
; 11(9): 2139-2144, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34479971
15.
FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-High Solid Tumors.
Clin Cancer Res
; 27(17): 4685-4689, 2021 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34083238
16.
FDA Approval Summary: Pembrolizumab for the First-line Treatment of Patients with MSI-H/dMMR Advanced Unresectable or Metastatic Colorectal Carcinoma.
Clin Cancer Res
; 27(17): 4680-4684, 2021 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33846198
17.
FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular Carcinoma.
Clin Cancer Res
; 27(7): 1836-1841, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33139264
18.
Subgroup Analyses in Oncology Trials: Regulatory Considerations and Case Examples.
Clin Cancer Res
; 27(21): 5753-5756, 2021 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34117032
19.
The FDA Oncology Center of Excellence Scientific Collaborative: Charting a Course for Applied Regulatory Science Research in Oncology.
Clin Cancer Res
; 27(19): 5161-5167, 2021 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33910935
20.
Neoadjuvant Therapy for Melanoma: A U.S. Food and Drug Administration-Melanoma Research Alliance Public Workshop.
Clin Cancer Res
; 27(2): 394-401, 2021 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33188142